Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
06:28am, Thursday, 18'th May 2023
Viatris pays a decent dividend and its line of business should be relatively safe. But it hasn't yet demonstrated its ability to maintain a stable top or bottom line.
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
02:26pm, Monday, 08'th May 2023
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Viatris Inc. (VTRS) Q1 2023 Earnings Call Transcript
12:37pm, Monday, 08'th May 2023
Viatris Inc. (NASDAQ:VTRS ) Q1 2023 Results Conference Call May 8, 2023 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Incoming Chief Executive Officer Rajiv M
Viatris (VTRS) Tops Q1 Earnings Estimates
09:54am, Monday, 08'th May 2023
Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.93 per share a year ago.
Want to Collect $1,100 in Dividends? Invest $20,000 in These 2 Stocks
09:45am, Thursday, 27'th Apr 2023
Viatris' business didn't grow at all last year, but the company's free cash flow is strong enough to support (and boost) its dividend payments. AT&T is coming off a tough quarter that spooked investor
4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates
12:11pm, Tuesday, 25'th Apr 2023
Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (A
8 Defensive Plays as Healthcare Stocks Stumble
11:13am, Wednesday, 19'th Apr 2023
Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.
Wall Street Thinks These 2 Value Stocks Could Soar
07:15am, Monday, 17'th Apr 2023
Continued Medicaid expansion bodes well for Centene. Viatris' drug pipeline should deliver modest growth in the years ahead.
1 "Safe" Stock to Avoid and 1 to Consider Buying in April
08:56am, Saturday, 15'th Apr 2023
In theory, the stock of companies that make generic drugs have the potential to be safe investments. Despite that, companies like Teva Pharmaceuticals aren't actually safe at all.
The 7 Most Undervalued Nasdaq Stocks to Buy in April 2023
07:15am, Tuesday, 04'th Apr 2023
Given the high concentration of tech and other types of growth plays trading on the Nasdaq exchange, it's easy to conflate the term “Nasdaq stocks” with growth stocks. However, there are in actual
Which Is the Better Dividend Stock: Viatris or Apple?
08:00am, Friday, 31'st Mar 2023
Viatris isn't growing quickly, but its dividend yield is high at the moment. Apple is growing steadily, and it has a long history of paying out to shareholders.
Generic drugs are most likely to face shortages due to market failures in affordability
05:26pm, Wednesday, 29'th Mar 2023
CNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.
Why Is Viatris (VTRS) Down 16.4% Since Last Earnings Report?
01:00pm, Wednesday, 29'th Mar 2023
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
Don't Be Fooled by These 3 Value Traps
09:10am, Tuesday, 28'th Mar 2023
In stock investing, these are called value traps. Value traps are equities that appear to be inexpensive because they have low valuations.
Viatris: The Value And The Value Trap
06:00pm, Sunday, 26'th Mar 2023
To say Viatris has been a sore disappointment since its spin-off, would be a massive understatement. The company came into its listing on very low valuations and had to do very little right to deliver
